Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 17,367 Cr.
- Current Price ₹ 1,660
- High / Low ₹ 1,678 / 900
- Stock P/E 57.7
- Book Value ₹ 129
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 19.6 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 12.8 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|
| 340 | 436 | 512 | 617 | 713 | 853 | 971 | |
| 195 | 256 | 308 | 289 | 439 | 504 | 544 | |
| Operating Profit | 145 | 180 | 205 | 328 | 274 | 349 | 426 |
| OPM % | 43% | 41% | 40% | 53% | 38% | 41% | 44% |
| 18 | 17 | 31 | 14 | 23 | 35 | 35 | |
| Interest | 1 | 1 | 1 | 1 | 6 | 10 | 4 |
| Depreciation | 18 | 19 | 21 | 28 | 50 | 54 | 54 |
| Profit before tax | 144 | 178 | 213 | 313 | 241 | 320 | 404 |
| Tax % | 30% | 33% | 21% | 25% | 26% | 26% | |
| 100 | 118 | 169 | 235 | 179 | 238 | 301 | |
| EPS in Rs | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 28.78 |
| Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 19% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 16% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 20% |
| Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,343 |
| 22 | 9 | 52 | 89 | 62 | 32 | 23 | |
| 69 | 72 | 118 | 94 | 144 | 191 | 174 | |
| Total Liabilities | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,550 |
| 189 | 230 | 240 | 546 | 573 | 593 | 590 | |
| CWIP | 3 | 19 | 141 | 18 | 74 | 173 | 188 |
| Investments | 151 | 229 | 199 | 142 | 74 | 138 | 151 |
| 343 | 285 | 361 | 477 | 592 | 611 | 621 | |
| Total Assets | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,550 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|
| 79 | 155 | 167 | 207 | 246 | ||
| -42 | -114 | -195 | -112 | -158 | ||
| -37 | -43 | 31 | -100 | -85 | ||
| Net Cash Flow | 0 | -1 | 3 | -4 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|
| Debtor Days | 236 | 133 | 131 | 105 | 119 | 117 |
| Inventory Days | 381 | 310 | 312 | 503 | 434 | 430 |
| Days Payable | 210 | 112 | 201 | 152 | 185 | 190 |
| Cash Conversion Cycle | 407 | 331 | 242 | 456 | 368 | 357 |
| Working Capital Days | 275 | 186 | 160 | 196 | 179 | 163 |
| ROCE % | 27% | 25% | 32% | 21% | 26% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 2d
- Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 For The Year Ended On 31St March, 2024 18 Apr
- Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015 18 Apr
-
Reply To Clarification Sought On Volume Movement
15 Apr - The company has disclosed all the material information/announcement or events from time to time to the exchange which may have bearing on the operation/performance of …
-
Clarification sought from Concord Biotech Ltd
15 Apr - Exchange has sought clarification from Concord Biotech Ltd on April 15, 2024, with reference to Movement in Volume.
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptPPT
-
Sep 2023Transcript PPT
Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.